Publications by authors named "RuiPing Dong"

Claim this Profile
[
[Correlation between albumin combined with diuretic therapy and mortality risk in septic patients with pre-existing congestive heart failure].
Qiaoman Huang, Zhiye Zou, Yixu Lin, Ruiping Dong, Yanran Chen

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Hyaluronic Acid Linear Stereoscopic Stack Volume Enhancement Injection Technique in Nasal Reshaping.
Ruiping Dong, Jiaqi Lei, Qingyang Liu

J Craniofac Surg· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of random quality control based on time -series model in ELISA detection of blood donors in Nanjing.
Wenping Han, Jingjing Bao, Polu Hu, Yang Liu, Rongrong Pang, Rui-Ping Dong

Heliyon· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-inferiority study to compare the effect of silica gel fiber dressing with alginate dressing on healing of venous leg ulcers.
Long Zhang, Jin Yang, Haofu Wang, Yunmin Cai, Wenjun Zhao, Ruiping Dong, Dongyang Liu

Wound Manag Prev· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and application of suspension static method in blood group screening of automated blood group analyzer.
Min Huang, Chengping Ma, Yan Li, Ruiping Dong, Rongrong Pang

Sci Rep· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Rui-Ping Dong

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
Kyriakos P Papadopoulos, Wael Harb, Cody J Peer, Qiong Hua, Siying Xu, Ruiping Dong

Oncologist· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RuiPing Dong. Interview by Asher Mullard.
RuiPing Dong

Nat Rev Drug Discov· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Polymorphism of human killer cell immunoglobulin-like receptor gene in Chinese Jiangsu Han population].
Yu-Dong Dai, Rui-Ping Dong, Hai-Lin DU

Zhongguo Shi Yan Xue Ye Xue Za Zhi· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The orphan response regulator CovR: a globally negative modulator of virulence in Streptococcus suis serotype 2.
Xiuzhen Pan, Junchao Ge, Ming Li, Bo Wu, Changjun Wang, Ruiping Dong

J Bacteriol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The involvement of sortase A in high virulence of STSS-causing Streptococcus suis serotype 2.
Changjun Wang, Ming Li, Youjun Feng, Feng Zheng, Yaqing Dong, Ruiping Dong

Arch Microbiol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145.
Michael J Kovacs, Donna E Reece, Deborah Marcellus, Ralph M Meyer, Sarah Mathews, Rui-Ping Dong

Invest New Drugs· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy].
Seiichi Yano, Motonori Yamaguchi, Rui-Ping Dong

Nihon Yakurigaku Zasshi· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Rui-Ping Dong

J Clin Oncol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Globalization of clinical trials].
Hideyuki Akaza, Masahiro Fukuoka, Atsushi Ohtsu, Michiyuki Usami, Tadashi Ikeda, Rui-Ping Dong

Gan To Kagaku Ryoho· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis